Scope Fluidics

Scope Fluidics Total Assets

The Total Assets of Scope Fluidics (SCP.WA) as of Oct 28, 2026 is 195.94 M PLN. In the previous year, Total Assets was 172.87 M PLN — a change of 13.34% (higher).

Total Assets

195.94 MPLN

YoY

13.34%

Last updated:

Total Assets of Scope Fluidics is 2025 195.94 M PLN. Total Assets of Scope Fluidics was 2024 172.87 M PLN. It decreases by 13.34% higher compared to the previous year.

The Scope Fluidics Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
13.91 M PLN
Jan 1, 2019
27.40 M PLN
Jan 1, 2020
41.31 M PLN
Jan 1, 2021
52.73 M PLN
Jan 1, 2022
346.16 M PLN
Jan 1, 2023
101.49 M PLN
Jan 1, 2024
172.87 M PLN
Jan 1, 2025
195.94 M PLN
The Scope Fluidics Total Assets history
YEARTotal AssetsYoY
195.94 MPLN+13.34%
172.87 MPLN+70.33%
101.49 MPLN-70.68%
346.16 MPLN+556.43%
52.73 MPLN+27.67%
41.31 MPLN+50.73%
27.40 MPLN+97.06%
13.91 MPLN-25.60%
18.69 MPLN+188.96%
6.47 MPLN-31.68%
9.47 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scope Fluidics stock

Total Assets of Scope Fluidics is 195.94 M PLN in 2025.

Total Assets of Scope Fluidics changed from 172.87 M PLN to 195.94 M PLN, representing a 13.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Scope Fluidics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Scope Fluidics

All Key Metrics — Scope Fluidics